Stayble’s clinical phase 2b study has now also started in the Netherlands
Stayble announces today, July 2, 2020, that the Company has initiated the first clinic in the Netherlands and now recruiting patients. The company has previously initiated clinics in Russia. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.The primary goal of the phase 2b trial is to demonstrate safety, tolerability and a clinically relevant reduction in pain in patients. The study will include some 100 patients and will be conducted at about 20 clinical sites in the Netherlands, Russia and Spain. The Company aims to recruit these patients during